Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early empagliflozin after acute coronary syndrome for left atrial functional recovery in adults with type 2 diabetes mellitus
IRCT20250302064896N5Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in acute coronary syndrome (ACS) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Left atrial strain, Left atrial ejection fraction and 1 more. Started Sep 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
acute coronary syndrome (ACS)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20250302064896N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250302064896N5.